Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Halozyme Therapeutics Inc HALO

Healthcare Biotechnology
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on... see more

Recent & Breaking News (NDAQ:HALO)

Halozyme To Host First Quarter 2020 Financial Results Webcast and Conference Call

PR Newswire April 28, 2020

Halozyme Announces Janssen Submits New Drug Application In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma

PR Newswire April 26, 2020

Halozyme Announces Change Of Location Of Annual Stockholders' Meeting

PR Newswire April 3, 2020

Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference

PR Newswire February 26, 2020

Halozyme Announces FDA Has Accepted Biologics License Application For Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Enhanze® Technology

PR Newswire February 25, 2020

Halozyme Reports Fourth Quarter and Full Year 2019 Results

PR Newswire February 24, 2020

Halozyme Announces CFO Transition

PR Newswire February 24, 2020

Halozyme To Host Fourth Quarter And Full Year 2019 Financial Results Webcast And Conference Call

PR Newswire February 10, 2020

Halozyme Provides 2020 Business Update And Financial Guidance

PR Newswire January 14, 2020

Halozyme Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference

PR Newswire January 3, 2020

Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium

PR Newswire December 12, 2019

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024

PR Newswire November 13, 2019

Bernadette Connaughton Appointed to Syneos Health Board of Directors

GlobeNewswire November 12, 2019

Halozyme Therapeutics, Inc. Announces Proposed Offering of $400 Million of Convertible Senior Notes due 2024

PR Newswire November 12, 2019

Halozyme Reports Third Quarter 2019 Results

PR Newswire November 12, 2019

Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint

PR Newswire November 4, 2019

Halozyme Announces Actions To Focus Strategy On ENHANZE® Drug Delivery Technology

PR Newswire November 4, 2019

Halozyme To Host Third Quarter 2019 Financial Results Webcast And Conference Call

PR Newswire October 21, 2019

Halozyme To Participate In 2019 Cantor Global Healthcare Conference

PR Newswire September 23, 2019

Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's Enhanze® Drug Delivery Technology

PR Newswire September 13, 2019